2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
Follow Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue: new trials by email Literature Review of Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue trials Research Report on Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone Lymphoma | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 138 | 2026-10-03 | 2026-10-13 |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 37 | 2025-08-25 | 2026-04-20 |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin - Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Completed | University of Washington | 42 | 2022-03-23 | 2026-05-13 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Ixazomib Citrate, Laboratory Biomarker Analysis, Rituximab - Chronic Lymphocytic Leukemia, Follicular Lymphoma | Phase 2 | Active not recruiting | University of Washington | 33 | 2016-05-19 | 2026-07-01 |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Follicular (5) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Waldenstrom Macroglobulinemia (3) · Lymphoma, B-Cell (2) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma, Non-Hodgkin (5) · Hematologic Diseases (4) · Lymphoma, B-Cell (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Chronic Disease (3) · Disease Attributes (3)
Magnetic Resonance Spectroscopy (3) · Biopsy (2) · Specimen Handling (2) · polatuzumab vedotin (2) · zanubrutinib (2) · CT-P10 (1) · LFB-R603 (1) · Lenalidomide (1) · Rituximab (1) · ibrutinib (1) · idelalisib (1) · ixazomib (1) · obinutuzumab (1) · pembrolizumab (1) · ublituximab (1)
University of Washington (2) · City of Hope Medical Center (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1) · Yazeed Sawalha (1)
United States (5)
Ajay K. Gopal (1) · Boyu Hu (1) · Geoffrey Shouse (1) · Ryan Lynch, MD (1) · Wei Ding (1) · Yazeed Sawalha, MD (1)
PMID 28424162, PMID 36385536, PMID 42600120
P30CA033572 (1), P50CA097274 (1), U10CA180888 (1)